Upcoming event

Tags

[68Ga]Ga-DPI-4452 PET/CT, 3D reconstruction, adjuvant pembrolizumab, advanced RCC, Article of the Month, Artificial intelligence, ASCO GU22, ASCO21, AUA21, augmented reality, belzutifan, biomarkers, Cabozantinib, CAIN trial, Carcinoma, CARE1 trial, ccRCC, CheckMate-214, CheckMate-9ER, Checkpoint Inhibitor, Chronic kidney disease, clampless surgery, clear cell renal cell carcinoma, Cryosurgery, cystic masses, diagnostics, durvalumab, EAU, EAU21, EAU22, EMUC2026, EMUC21, EMUC22, enucleoresection, ERUS 2026, ERUS22, ESMO21, ESMO25, expert interview, first-line, first-line treatment, Frail patient​, Glomerular filtration rate, Guidelines, histology, histotripsy, imaging, IMDC risk model, immunotherapy, International Metastatic Renal Cell Carcinoma Database Consortium, intraoperative cyst rupture, intraoperative ultrasound, Kidney cancer, kidney-preserving, Laparoscopy, lenvatinib, localised renal cell carcinoma, Lymph node metastases, Lymph nodes, Metastasectomy, metastatic clear-cell renal cell carcinoma, metastatic disease, metastatic RCC, MK-1308A, Mortality, mRCC, neoadjuvant immunotherapy, Neoplasm metastasis, Neoplasm recurrence, Nephrectomy, Nephron-sparing surgery, Nivolumab, oligometastatic renal cell carcinoma, omRCC, Overall survival, papillary tumour, Partial nephrectomy, patient reported outcomes, PD-L1+, PE-PE trial, pembrolizumab, precision therapy, Prognostication, quality of life, Radical nephrectomy, Radical surgery, RAMPART trial, RCC, Renal cancer, Renal cell, Renal cell carcinoma, Renal Cell Carcinoma guidelines, Renal cryoablation, Renal function, Renal Transplantation, Renorrhaphy, resected renal cell carcinoma, risk stratification, robot-assisted partial nephrectomy, Robotic, robotic partial nephrectomy, Robotic prostatectomy, Robotic surgery, selective clamping, stereotactic body radiation therapy, Survival outcome, Suture, sutureless partial nephrectomy, Targeted therapies, TKIs, Treatment response, tumour enucleation, tumour genomics, tumour pseudocapsule rupture, tyrosine kinase inhibitors, Urological surgery, UROonco2025, UROonco24, UROonco25, UROwebinar, Webinar, zero-ischaemia surgery
Show all

Characterizing changes in muscle mass after radical nephrectomy for stage ii-iv clear cell renal cell carcinoma

Journal of Urology, September 2021

Impact of tobacco use on postoperative morbidity and mortality following surgery for renal masses

Journal of Urology, September 2021

Major adverse cardiovascular events following partial nephrectomy: a novel risk index

Journal of Urology, September 2021

The changing trends of image guided biopsy of small renal masses before intervention- an analysis of european multinational prospective eureca registry

Journal of Urology, September 2021

Oncologic outcomes following partial nephrectomy versus percutaneous cryoablation: a propensity score matched analysis

Journal of Urology, September 2021

End-stage kidney disease after partial and radical nephrectomy among patients with severe chronic kidney disease

Journal of Urology, September 2021

Association of tumor histology on impact of lymph node dissection on survival in t2-t3 renal cell carcinoma: analysis of the national cancer database

Journal of Urology, September 2021

Active surveillance in nonhereditary bilateral multifocal type i papillary renal cell carcinoma

Journal of Urology, September 2021

Impact of surgical approach (open vs. minimally invasive) on oncological outcomes after nephrectomy for localised renal cell carcinoma: a recur database project

Journal of Urology, September 2021

Surgeon-specific variation in operative outcomes for patients with clinical T1 renal masses

Journal of Urology, September 2021

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study

The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management

European Urology, Volume 79, Issue 4, April 2021, Pages 468-477

PreviousNext